Lyrica (pregabalin) is a new anticonvulsant medication approved by the European Community (July 2004) and the U.S. FDA (September 2004) for the treatment of epilepsy and painful diabetic neuropathy.
Pregabalin is a derivative of Neurontin etc. (Gabapentin). Both drugs share a similar mechanism of action: binding to calcium channels and modulating calcium influx as well as influencing GABA (gamma-aminobutyric acid). GABA is a neurotransmitter, a chemical that carries messages between brain nerve cells. GABA inhibits the transmission of nerve signals, thereby reducing nervous excitation.